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Background: PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are thought to be the central transducers of
oncogenic signals in solid malignancies, and there has been a lot of enthusiasm for developing inhibitors of these
pathways for cancer therapy. Some preclinical models have suggested that combining inhibitors of both parallel
pathways may be more efficacious, but it remains unknown whether dual inhibition with high enough
concentrations of the drugs to achieve meaningful target inhibition is tolerable in a clinical setting. Furthermore,
the predictive factors for dual inhibition are unknown.
Methods: Non-small cell lung cancer (NSCLC) cell lines (n=12) with the most frequent oncogenic backgrounds
(K-Ras mut n=3, EGFR mut n=3, ALK translocated n=3, and triple-negative n=3) were exposed to PI3K inhibitors
(ZSTK474, PI-103) or MEK inhibitor (CI-1040) alone or in combination and analysed with an MTS growth/cytotoxicity
assay and statistically by combination index analysis. The activity of the intracellular signaling pathways in response
to the inhibitor treatments was analysed with a western blot using phospho-specific antibodies to AKT, ERK1/2, S6,
and 4E-BPI. For the differential dosing schedule experiments, additional breast and colon cancer cell lines known to
be sensitive to dual inhibition were included.
Results: Two of the 12 NSCLC cell lines tested, H3122 (ALK translocated) and H1437 (triple-negative), showed
increased cytotoxicity upon dual MEK and PI3K inhibition. Furthermore, MDA-MB231 (breast) and HCT116 (colon),
showed increased cytotoxicity upon dual inhibition, as in previous studies. Activation of parallel pathways in the
dual inhibition-sensitive lines was also noted in response to single inhibitor treatment. Otherwise, no significant
differences in downstream intracellular pathway activity (S6 and 4E-BPI) were noted between PI3K alone and dual
inhibition other than the increased cytotoxicity of the latter. In the alternative dosing schedules two out of the four
dual inhibition-sensitive cell lines showed similar cytotoxicity to continuous PI3K and short (15min) MEK inhibition
treatment.
Conclusions: Therapy with a dual PI3K and MEK inhibitor combination is more efficient than either inhibitor alone
in some NSCLC cell lines. Responses to dual inhibition were not associated with any specific oncogenic genotype
and no other predictive factors for dual inhibition were noted. The maximal effect of the dual PI3K and MEK
inhibition can be achieved with alternative dosing schedules which are potentially more tolerable clinically.
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Constitutive activation of oncogenic pathways occurs in
cancers with very high frequency, and this is thought to be
a central factor behind the hallmarks of cancer phenotypes,
such as cycle progression, inhibition of apoptosis and
metabolic reprogramming. The PI3K-AKT and RAS-RAF-
MEK-ERK pathways are thought to play a central role in
transmitting these oncogenic signals. Frequent cancer-
associated genetic alterations such as receptor mutations
or amplifications, mutations in intermediate signal trans-
ducers such as Ras, Raf or PI3KCA and inactivation of
certain tumor suppressors such as PTEN lead to constitu-
tive activation of these pathways [1].
The high frequency of cancer-associated genetic altera-
tions causing constitutive activation of PI3K-AKT and
RAF-MEK-ERK and the addiction of cancer cells to their
signals have led to enthusiasm for developing inhibitors of
these pathways. In view of the central role of such path-
ways in transmitting upstream oncogenic signals, their
inhibition could be an effective therapy for various cancer
genotypes. Some cancer genotypes have been identified in
preclinical studies as responders to specific inhibitors of
the pathways. HER2 amplified breast cancers have been
shown to respond to PI3K inhibitors [2], while B-Raf
mutant melanomas [3] and triple-negative breast cancers
are repressed by MEK inhibitors [4]. The effectiveness of
single pathway inhibition could be suppressed by de novo
dependence on multiple signaling pathways or feedback
activation of other signaling pathways in response to the
inhibition of a single pathway [2,5]. This has led to studies
combining PI3K or AKT and MEK inhibitors. Dual inhi-
bition has shown increased efficiency in various cancer
genotypes in pre-clinical studies [2,4,6,7] and numerous
early-phase clinical studies are in progress. Clinical studies
have shown the simultaneous inhibition of multiple path-
ways to be in all probability more toxic than inhibition of a
single pathway, and no optimal dose has been established.
PI3K-mTOR inhibitors may be divided into PI3K inhibi-
tors (such as ZSTK474), dual PI3K–mTOR inhibitors
(such as PI-103) and mTOR inhibitors (rapalogs). Rapalog
mTOR inhibitors are known to induce IRS-1-mediated,
upstream feedback activation of PI3K-AKT [8], which is
thought to be important for the limited clinical efficiency
of the therapy for most cancers, including NSCLC. PI3K
and PI3K/mTOR inhibitors should lack such feedback
activation and theoretically be more active. Numerous
early phase clinical trials are currently testing both single
PI3K and dual PI3K/mTOR inhibitors, but it is unknown
whether either is more efficient, although it is likely that a
drug which hits multiple targets will be more toxic in a
clinical setting.
Current oncological therapies have modest disease
modifying effects in cases of non-small cell lung cancer
(NSCLC), even though some disease subgroups responsiveto targeted therapy have been identified in recent years.
These include EGFR mutant (10-30% of patients) [9,10]
and ALK translocated (~5%) [11,12], in which patients are
highly responsive to EGFR or ALK tyrosine kinase inhibi-
tors (TKI) [13,14]. Furthermore, other major oncogenic
disease subgroups include the K-Ras mutant (~25% of
patients), which is thought to be undruggable with cur-
rently available pharmacological agents [15].
We set out here to investigate dual inhibition with
PI3K and MEK in non-small cell lung cancer (NSCLC)
cell lines of various genotypes. Dual inhibition is shown
to be a more effective form of therapy in some cell lines.
This study also addresses administration schedules for




The cell lines used here included NSCLC lines with a
K-Ras mutation (A549, H358, H441), EGFR mutation
(H1975, HCC827, PC-9), ALK translocation (DFCI032,
H2228, and H3122) and the triple negative genotype
(A431, H1437, H1581), a basal-like breast cancer line
MDA-MB231 and HCT116, a K-Ras mutant colorectal
cell line. The NSCLC cell lines were kind gifts from
Dr. Pasi Jänne (Dana-Farber Cancer Institute, Boston,
USA), and the breast and colorectal lines from Dr. Peppi
Koivunen (Oulu University, Oulu, Finland). The cell lines
were cultured in RPMI-1640 supplemented with 5 or 10%
fetal bovine serum and 100 IU/ml penicillin and strepto-
mycin. All the cell culture reagents were purchased from
HyClone (Logan, UT).
Inhibitors
The following inhibitors were used: CI-1040, PI-103,
ZSTK474 (Alexis Biochemicals; Lausen, Switzerland), and
TAE684 (a kind gift from Dr. Nathanael Gray, Dana-Farber
Cancer Institute, Boston, USA). All the inhibitors were
dissolved in DMSO to a final concentration of 10mM and
stored at −20°C. The drug solutions for the experiments
were prepared from a 10mM stock solution immediately
before use. MEK inhibitor CI-1040 (PD-184352), a specific
small-molecule drug that inhibits MEK1/MEK2, is thought
to act as an allosteric inhibitor of MEK, since it is known
not to compete with the binding of either ATP or protein
substrates. CI-1040 blocks ERK phosphorylation and inhi-
bits the growth of multiple human tumor cell lines and
tumor growth in xenograft models. It has been shown that
the inhibitory effect of CI-1040 on cell growth is rapidly
reversed after it is removed from the growth medium [16].
ZSTK474 is a small-molecule PI3K inhibitor which has
shown to be a potential antitumor agent against a human
cancer xenograft in vivo with no toxicity to any critical
organs [17]. It inhibits all four PI3K isoforms, most strongly
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binding-pocket of the protein. In addition, the molecule is
significantly specific to PI3K, since even when administered
at high concentrations it only weakly inhibits the mTOR
complex, which contains a conserved PI3K domain [18].
PI-103 is a pyridofuropyrimidine compound that selectively
inhibits PI3Kα and mTOR signaling, prevents cell prolifera-
tion and invasion, causes G0-G1 cell cycle arrest and
reduces tumor growth in glioma xenografts [19]. The in-
hibitor has also shown significant antitumor potency in
NSCLC cell lines [20].
Cytotoxicity/cell growth assay
Cells were plated onto 96-well plates with three to six
parallel wells for each treatment, the experiments being
replicated at least three times. The inhibitor treatments
were started on the following day, and the plates were
developed 72h later using an MTS reagent mix ([3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt], Promega;
Madison, WI) supplemented with phenazine methosul-
fate (Sigma-Aldrich; St. Louis, MO) according to the
manufacturer’s guidelines. The absorbances were read
on a plate reader (Athos Labtec Instruments; Salzburg,
Austria) at a wavelength of 488nm. The data were dis-
played graphically using GraphPad Prism (GraphPad Soft-
ware; La Jolla, CA), with the absorbance in the non-treated
wells as the reference value (100%). The combination index
(CI) was calculated using Calcusyn software (BIOSOFT,
Cambridge, UK), and a 3.3:1 ratio of the PI3K inhibitors to
the MEK inhibitor was used in the CI analysis. CI values at
ED50 are presented.
Western blot analysis
The cells were plated onto 6-well plates and treated with
the drugs 24-48h later for 6 or 72 h, after which they
were lysed in RIPA buffer (1% Igepal CA-630, 20 mM
Tris–HCl pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM
EDTA, 1 mM sodium orthovanadate, 10 μg/mL Aproti-
nin, 10 μg/mL Leupeptin, and 10 μg/mL Pepstatin).
Protein concentrations were measured using the Bio-
Rad Protein Assay (Bio-Rad; Hercules, CA) and the con-
centrations in individual samples were equalized before
adding 3x Laemmli buffer to a final concentration of 1x.
Equal amounts of protein were run on 7.5% SDS-PAGE
gels, transferred to PVDF membranes, probed with the
antibodies and developed using the ECL chemilumines-
cence system (Millipore; Billerica, MA) for detection on
radiographic films, which were scanned to an electronic
format. All the antibodies used were from Cell Signaling
Technologies (Danvers, MA): pAKT (S473), AKT, pERK
(T202/Y204), ERK, pS6 (Thr389), S6, p4E-BP1 (Thr37/46),
4E-BP1, cleaved PARP. Anti-rabbit HRP conjugated anti-
body was used as a secondary antibody.Pathscan analysis
The PathScan analysis was carried out with the PathScanW
RTK Signaling Antibody Array kit (Cell Signaling Tech-
nologies, Danvers, MA) according to the manufacturer’s
guidelines. In brief, cells were plated on plates of diam-
eter 6 cm and drugged the following day for 24 h.
Whole cell lysates were collected, protein concentra-
tions were determined using the Bio-Rad Protein Assay
(Bio-Rad, Hercules, CA) and the protein concentrations
were equalized. The lysates were applied to nitrocellulose
membranes and incubated over night, washed, exposed to
the secondary antibodies, developed with ECL and imaged
with a Fujifilm LAS-3000 Luminescent Image analyzer
and the ImageReader LAS-3000 program. The array target
map can be found through the manufacturer’s homepage
(http://www.cellsignal.com/products/7982.html).
Results
Dual inhibition of PI3K and MEK in cancer cell lines
The inhibitors used were ZSTK474 (PI3K inhibitor) and
PI-103 (PI3K and mTOR inhibitor) and CI-1040 (MEK
inhibitor). We first addressed the effects of these inhibi-
tors alone in the NSCLC lines A549 (K-Ras mutant),
HCC827 (EGFR mutant) and H3122 (EML4-ALK trans-
located), representing the three most frequent oncogenic
genotypes of the disease, to establish concentration frames
for the target inhibition. In the Western blots ZSTK474 at
a 3.3μM concentration induced complete downregulation
of pAKT, an immediate downstream target of PI3K, while
PI-103 induced a similar inhibition at concentrations of 1
to 3.3 μM (Figure 1A). pS6 downregulation correlated
highly with pAKT downregulation (Figure 1A). The MTS
cytotoxicity assay showed a major reduction in the num-
ber of viable cells in all the cell lines with similar concen-
trations of both inhibitors, which were closely correlated
with the concentrations inducing complete inhibition of
pAKT in Western blot analysis (Figure 1A,C). CI-1040
induced complete inhibition of ERK1/2, an immediate
downstream target of MEK, at a 1 μM concentration
(Figure 1B). Only the H3122 line showed any marked re-
duction in cell viability in the MTS assays in response to
increasing concentrations of the inhibitor, correlating with
maximal target inhibition, while the other lines displayed
minor changes in viability, except for the 10 μM treatment
in HCC827, despite the achieving of complete inhibition
of pERK1/2 in all the lines tested at 1 μM (Figure 1C).
Dual inhibition of PI3K and MEK was tested in a panel
of NSCLC lines (n=12) with the K-Ras (n=3), EGFR
(n=3), ALK (n=3), or triple-negative (n=3) oncogenic
genotypes. Analogously to the cell lines in the prelimin-
ary experiments, all the cell lines tested here showed a
major reduction in cell growth in response to the PI3K
inhibitors alone, with no significant differences between
ZSTK474 or PI-103 (Figure 2A, eight of the twelve lines
Figure 1 PI3K and MEK inhibitors in NSCLC cell lines. NSCLC cell lines A549, HCC827 and H3122 were exposed to increasing concentrations
of the PI3K inhibitors ZSTK474 and PI-103 and the MEK inhibitor CI-1040. (A) Western blot analysis of phosphorylated AKT (pAKT), S6 (pS6), and
ERK1/2 (pERK1/2) and their corresponding total proteins (AKT, S6, ERK1/2) in response to the PI3K inhibitors. (B) Western blot analysis of
phosphorylated ERK1/2 (pERK1/2) and AKT (pAKT) and their corresponding total proteins (ERK1/2, AKT) in response to the MEK inhibitor.
(C) MTS assay for cytotoxicity in response to the PI3K inhibitors or MEK inhibitor. The cells were exposed to the inhibitors for 6h in the Western
blot experiments and 72 h in MTS assays. Error bars show SD.
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cited variable responses with the majority of cell lines,
showing only minor inhibition of growth or none at all.
When the cell lines were exposed to dual, concurrent in-
hibition of PI3K and MEK, two out of 12 tested cell
lines, H3122 and H1437, showed marked additional
cytotoxicity compared with treatment with a single agent
(Figure 2A). The results were submitted to combination
index (CI) analysis and average CI values were calculated
based on combinations of ZSTK474 and PI-103. This
analysis grouped the cell lines into three categories: an-
tagonism (n=5, CI 1.10-3.3), nearly additive or slight
synergy (n=5, CI 0.7-1.10), and synergy or strong synergy(n=2, CI <0.7) (Table 1). Visual assessment of the dual
inhibition in MTS curves did not suggest any major
antagonism of treatment in any of the lines tested, how-
ever, since the combination treatment curves in the cell
lines with antagonistic CI values closely followed the sin-
gle PI3K inhibitor treatment curves (Figure 2A). There
was no correlation between the cancer genotypes in
responsiveness to the dual inhibition, since an ALK
translocated line (H3122) and a triple-negative negative
line (H1437) showed synergistic responses to dual inhi-
bition (Figure 2A, Table 1). The NSCLC lines showing
synergistic responses to dual inhibition seemed to be
more responsive to low concentrations (<1 μM) of the
Figure 2 (See legend on next page.)
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Figure 2 PI3K and MEK inhibitors and their combinations in cancer cell lines. The cells were exposed to specific treatments for 72 h and
analyzed with the MTS cytotoxicity assay. The single inhibitor treatments are represented with dashed lines and their combinations with
continuous lines. (A) NSCLC cell lines. The cell lines are placed in four groups based on their oncogenic genotype (K-Ras mutant, EGFR mutant,
ALK translocated, and triple wild type). (B) Breast cancer line MDA-MB231 and colorectal cancer line HCT116, known from the previous literature
to be sensitive to dual PI3K and MEK inhibition. Error bars show SD.
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single inhibitor results, the lines sensitive to dual inhi-
bition showed only a minor difference between the acti-
vities of the different PI3K inhibitors in combination
with the MEK inhibitor.
Based on a literature search [4,7], additional cell lines
known to be responsive to dual PI3K and MEK inhib-
ition were studied. MDA-MB231, a basal-like breast
cancer line, and HCT116, a K-Ras mutant colorectal
line, were exposed to single inhibitors or dual inhibition
and analyzed with the MTS assay. As in the previous
work, both the cell lines showed synergistic responses to
dual inhibition (Figure 2B, Table 1). PI-103 was markedlyTable 1 Combination index analysis




























H1975 PI-103 1,19less effective than ZSTK474 in the HCT116 cell line,
while, like all the NSCLC cell lines, MDA-MB231
responded similarly to both PI3K inhibitors (Figure 2B,
Table 1). Interestingly, we did not see any differences in
target inhibition between ZSTK474 and PI-103 in the
HCT116 line (Figure 3A), so that the mechanism of dif-
ferential efficiency remains unknown.
The lines H3122, H1437, MDA-MB231, and HCT116,
which were sensitive to dual inhibition, were further
analyzed with Western blot analysis for cleaved PARP, a
well-characterized marker of apoptosis. No cleaved
PARP was detected in any of the cell lines following the
single agent treatments (Figure 4A), but when dualAverage CI Range Significance




0,71 0,7-0,85 Moderate synergism
0,79 0,7-0,85 Moderate synergism
0,885 0,85-0,9 Slight synergism
0,93 0,90-1,10 Nearly additive
1,07 0,90-1,10 Nearly additive
1,19 1,10-1,20 Slight antagonism




Figure 3 Activity of the central cell signaling pathways in response to dual PI3K and MEK inhibition in dual inhibition-sensitive cancer
cell lines. (A) Western blot analysis for pAKT, pERK1/2, pS6 and p4E-BP1 and their corresponding total proteins in response to treatment with the
PI3K inhibitors ZSTK474 and PI-103 and the MEK inhibitor CI-1040 singly or in combination for 6h. (B) Western blot analysis of the same proteins
as in panel A when the inhibitor combinations were administered alternately for the times indicated (15 min or 6 h). The cells were exposed to
dual inhibition for 15 min, the inhibitors were washed out and treatment was continued with a single inhibitor for an additional 6 h.
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tered, marked PARP cleavage was seen in the H3122 line
but not in the other lines tested (Figure 4A).Effect of dual inhibition on cell signaling
The NSCLC (H3122 and H1437), breast cancer (MDA-
MB231) and colon cancer (HCT116) lines, which showing
major synergy upon dual inhibition, were further studied
for cell signaling in response to the inhibitors. All the cell
lines downregulated pAKT and its downstream target pS6
completely in response to 6h of treatment with the PI3K
inhibitor ZSTK474 or PI-103 (3.3 μM) (Figure 3A). Down-
regulation of p4E-BP1 was also noted with all the cell lines
tested, but it was complete only in the H3122 cell
line (Figure 3A). Furthermore, concurrent activation of
pERK1/2 was recognized in the H3122, MDA-MB231 and
HCT116 cell lines during PI3K inhibitor treatment
(Figure 3A). When the cell lines were treated with the
MEK inhibitor CI-1040 (1 μM, 6 h), complete (H3122,
H1437) or marked (MDA-MB231, HCT116) downregula-
tion of pERK1/2 was seen (Figure 3A). This was accom-
panied by upregulation of pAKT in the H3122 and
MDA-MB231 lines, but not by upregulation of pS6 or
p4E-BP1 (H3122) (Figure 3A). p4E-BP1 was markedlyupregulated in the MDA-MB231 line in response to CI-
1040 treatment (Figure 3A).
When the PI3K and MEK inhibitors were administered
simultaneously the inhibition of the targets was similar
to that seen with single inhibitor treatment (Figure 3A).
Dual inhibition was able to overcome the single inhibitor-
induced stimulation of parallel pathway activation
(Figure 3A). We were not able to detect any significant
difference in the activity of either pS6 or p4E-BP1 fol-
lowing dual inhibitor treatment as compared with the
single PI3K inhibitor treatments (Figure 3A).
Further analysis of the dual inhibition of the central
RTKs and signaling nodes was carried out with
the PathScan Antibody Array, which investigates the
phosphorylation status of 28 RTKs and 11 signaling
nodes concurrently. Attention was focused on the dual
inhibition-sensitive H1437 and MDA-MB231 lines. A low
level of RTK activation was noted in untreated cells of
both cell lines, H1437 showing some activity with c-MET
(Figure 5), while in the signaling nodes, pAKT, S6 and
ERK1/2 showed activity in both cell lines and Src activity
was also noted in H1437. In the drug-treated cells,
ZSTK474 (24 h) was able to inhibit both AKT and S6
phosphorylation, S6 showing a more pronounced effect
(Figure 5). Furthermore, ZSTK474 induced a marked
Figure 4 Apoptotic response to dual PI3K and MEK inhibition in dual inhibition-sensitive cancer cell lines. (A) Western blot analysis for
cleaved PARP (cPARP) in the H3122, H1437, MDA-MB231 and HCT116 lines treated with the PI3K inhibitors ZSTK474 and PI-103, the MEK inhibitor
CI-1040, or their combinations for 48 h. (B) Western blot analysis for cleaved PARP in the H3122 cell line treated for 15min with dual inhibition
and with the single inhibitor indicated for an additional 48 h, or with the ALK inhibitor TAE684 for 15 min. (C) Western blot analysis for cleaved
caspase-3 in the H3122 line with indicated treatments and exposure times.
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(Figure 5). CI-1040 (24 h) effects were limited to the in-
hibition of ERK1/2 activity. When dual inhibition with
ZSTK474 and CI-1040 was administered, downregulation
of both pAKT/S6 and ERK1/2 was noted, but otherwise
no marked difference was evident relative to the single
agent treatments (Figure 5). The results suggest specificity
of the inhibitors for their targets and the existence of
broad feedback activation.
Alternative dosing of dual inhibition
Even though dual inhibition of PI3K and MEK was identi-
fied as an effective form of cancer therapy based on the
in vitro models, administration of both drugs at doses in-
ducing major downregulation of the target for long peri-
ods of time may be too toxic in a clinical setting. We
therefore set out to investigate concurrent administrationFigure 5 PathScan analysis of dual inhibition of the central RTKs and
cell lines were left untreated (0), treated with 3.3μM ZSTK474, 1 μM CI-1040
antibody array assay for the phosphorylation status of 28 central RTKs (bott
ERK1/2 signals are circled. The whole array target map is available through
7982.html).of PI3K and MEK inhibitors to cell lines sensitive to dual
inhibition with alternative dosing schedules. The MTS
assays showed that for maximal reduction in the number
of living cells in all the lines, dual inhibition needed to be
administered for longer periods of time. The therapy was
significantly more effective when it was administered
throughout the 72 h experiment as compared with 15
min, 4 h or 24 h periods (Figure 6). Interestingly, maximal
cytotoxicity was seen in the ALK translocated H3122 line
even with short courses of ALK inhibition (15 min), while
similar cytotoxicity was seen with 72 h inhibition of PI3K
and MEK concurrently (Figure 6), even though both
approaches induced major inhibition of phosphorylated
AKT and ERK in Western blots after 6 h treatments
(Figure 3A).
Since the results showed that dual inhibition needed to
be administered for longer periods of time for maximalsignaling nodes. The dual inhibition-sensitive MDA-MB231 and H1437
, or their combination for 24 h and analyzed with the PathScan
om 13 rows) and 11 signaling nodes (top five rows). The AKT, S6 and
the manufacturer’s homepage (http://www.cellsignal.com/products/
Figure 6 Alternative dosing schedules for concurrent PI3K and MEK inhibition in dual inhibition-sensitive cancer cell lines. The cell lines
were exposed to the inhibitors (ZSTK474 and PI-103 3.3 μM, CI-1040 1 μM, or their combinations) for the times indicated and analyzed with the
MTS assay after 72 h. H3122, an ALK translocated and ALK inhibition-sensitive NSCLC line, was also exposed to the 0.1 μM ALK inhibitor TAE684
(TAE) for the times indicated. Error bars show SD. A dashed line is inserted at the level of the single inhibitor treatment inducing maximal growth
inhibition to facilitate comparison with the dual inhibition treatments.
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inhibitors are required throughout the period of exposure.
The dual inhibition-sensitive cell lines were exposed to
one inhibitor throughout the treatment period (72 h)
while the other inhibitor was administered concurrently
for 15 min, 4 h or 24 h at the beginning of the drug expos-
ure. The results varied significantly between the cell lines
tested. In the H1437 and MDA-MB231 lines concurrent
inhibition of PI3K and MEK for 15 min with continued
PI3K inhibition for 72 h achieved similar cytotoxicityto concurrent inhibition for 72 h (Figure 6). Conversely,
when these lines were exposed to the MEK inhibitor
throughout the treatment period, short concurrent expo-
sures (15 min, 4 h or 24 h) to PI3K inhibitors did not in-
duce any comparable cytotoxicity (Figure 6). On the other
hand, the effects of dual inhibition with PI-103 occurred
faster in the H1437 line than with ZSTK474, since shorter
exposures to the drug (24 h) seemed to be sufficient for
maximal cytotoxicity as compared with 72h of ZSTK474
(Figure 6). In the case of the H3122 and HCT116 lines,
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tered throughout the treatment period for maximal cyto-
toxicity (Figure 6).
We next investigated alternative dosing of the dual in-
hibition of cell signaling. The dual inhibition-sensitive
lines were exposed to the PI3K inhibitors and MEK in-
hibitor concurrently for 15 min, after which treatment
was continued with a single inhibitor for the remainder
of the 6 h period. pAKT downregulation was complete
or nearly complete when the cells were treated for only
15 min and with PI3K inhibitors for 6 h (Figure 3B),
while conversely, pERK1/2 recovered completely in 6 h
when the cells were treated with the MEK inhibitor for
15 min (Figure 3B). Interestingly, we were able to see
some recovery in the activity of the downstream targets
of AKT when the PI3K inhibitors were administered for
15min despite the remaining pAKT downregulation.
The pS6 signal was able to recovery in the MDA-MB231
(with ZSTK474) and HCT116 (with both PI3K inhibi-
tors) lines after short PI3K administration (Figure 3B).
Furthermore, p4E-BP1 recovery was noted in the H3122
(with ZSTK474), MDA-MB231 (with ZSTK474), and
HCT116 (with both PI3K inhibitors) lines (Figure 3B).
Interestingly, MEK inhibitor treatment induced upregu-
lation of p4E-BP1 in the MDA-MB231 line (Figure 3A),
and marked downregulation p4E-BP1 was noted only
with PI-103 (PI3K and mTOR inhibitor) in the alterna-
tive dosing experiments, but not with ZSTK474 (with a
PI3K inhibitor alone) (Figure 5), suggesting mTOR-
mediated activation of 4E-BP1 in response to MEK in-
hibition. TAE684, an ALK inhibitor, treatment was also
included in the experiments conducted with the H3122
line, and this induced comparable pAKT, pERK1/2, and
pS6 downregulation to that achieved with dual inhibition,
whereas no change in p4E-BPI was noted (Figure 3B).
Some recovery of pAKT and pS6 was seen after a short
treatment with TAE684 (Figure 3B).
We went on further to analyze whether the alternative
dosing could also result in apoptosis in the H3122 cell line,
the only line identified as inducing apoptosis in response
to dual inhibition. When the cells was treated for 15 min
with dual inhibition and treatment with either the PI3K
inhibitors or the MEK inhibitor was continued for 48 h,
marked PARP cleavage was seen in all the treatments
(Figure 4B). Furthermore, 15 min treatment with an ALK
inhibitor resulted in marked PARP cleavage (Figure 4B).
Cleaved PARP results were further verified with western
blot analysis for cleaved caspase-3, another marker for
apoptosis. Cleaved caspase-3 was detected with concurrent
PI3K and MEK, or ALK inhibition while no signal was seen
in PI3K or MEK inhibitor treatments. Conversely to
cleaved PARP, the cleaved caspase-3 signal was much lower
in alternative dosing schedules compared to continuous,
concurrent PI3K and MEK inhibition (Figure 4C).Discussion
The PI3K-AKT and RAS-RAF-MEK-ERK signaling path-
ways are thought to be the central mediators of onco-
genic signals in solid malignancies. Multiple inhibitors
targeting PI3K, AKT, RAF and MEK are under develop-
ment for cancer therapy, but early-phase clinical trials
suggest that the single agent efficiency of such inhibitors
seems to be limited, except in the case of the Raf mutant
melanoma, where both RAF and MEK inhibitors have
high clinical activity. There is preclinical evidence that
combining the inhibitors of both pathways provides
more efficient cancer therapy [2,4,6,7], and some early-
phase clinical trials are under way to test this approach.
We investigated here the dual pharmacological inhib-
ition of PI3K and MEK in NSCLC cell line models with
specific oncogenic genotypes. All the cell lines tested
were highly responsive to single-agent PI3K inhibitors,
showing a strong correlation with maximal target inhib-
ition. This suggests that the PI3K-AKT pathway has a
central role in transmitting oncogenic signals from vari-
ous upstream sources, and therefore the responses to
pathway inhibition are not limited to any specific cancer
genotype. Furthermore, the data suggest a central role
for pathway activation in the proliferation of carcinomas.
The cytotoxicity of PI3K inhibitors seemed to be com-
parable when a PI3K (ZSTK474) or PI3K/mTOR (PI-
103) inhibitors alone were used, suggesting that only
PI3K inhibition matters for cytotoxicity, as administra-
tion of the MEK inhibitor seemed to have limited activ-
ity or none at all in the models tested. Two out of the
twelve cell lines tested showed significantly increased
cytotoxicity in response to the concurrent administra-
tion of PI3K and MEK inhibitors. Analogously to previ-
ous studies, the activity of dual inhibition was not
associated with any specific oncogenic genotype, since
ALK translocation-positive (H3122) and triple-negative
(H1437) cell lines were the most responsive ones [6]. In
MEK inhibition-sensitive models. such as triple-negative
breast or K-Ras mutant colorectal cancers have shown
additive cytotoxicity or reversal of resistance when MEK
inhibitors have been combined with inhibitors of the
PI3K-AKT-mTOR pathway [4,7]. It is interesting to note
that the dual inhibition-sensitive NSCLC lines identified
here showed some cytotoxicity in response to low con-
centrations of MEK inhibitors (<1 μM), thereby differing
from the other lines tested, which showed no response
or a response only to high concentrations of the inhibi-
tor. Furthermore, the K-Ras, EGFR and ALK wild-type
cell H1437 is of a rare oncogenic genotype, a MEK1 mu-
tant, and has previously been identified as being sensi-
tive to MEK inhibitor treatment alone [21]. Based on the
current data and previously reported findings, one could
speculate that dual PI3K and MEK inhibition therapy
could be the most efficient for cancers that show some
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survival. Mechanistically, sensitivity to dual PI3K and
MEK inhibition remains to be elucidated. It is likely that
the responses are not associated with any specific onco-
genic genotype but rather with inhibition of the effects
of feedback activation induced by the inhibition of one
pathway on the other. If this also holds good in vivo, it is
likely to make the selection of patients for such treat-
ment difficult, since no predictive biomarkers of feed-
back activation exist.
Even though dual inhibition of PI3K-AKT and MEK
has been identified as an effective cancer therapy in pre-
clinical models, it questionable whether this therapy is
tolerable in a clinical setting concentrations high enough
to achieve sufficient target inhibition. Early-phase clin-
ical trials are in progress to test different doses and
dosing schedules, but the optimal administration for
maximal efficiency and tolerability remains to be eluci-
dated. In the light of recent data from the ASCO 2012
Annual Meeting, PI3K and MEK inhibitor combination
treatments are now being tested in concurrent and inter-
mittent schedules [22,23]. The tolerability of intermittent
administration may enable higher doses of the agents to
be administered than with continuous concurrent treat-
ment [23]. The cell line model data presented here
suggest that even short courses of concurrent adminis-
tration can cause marked cytotoxicity and/or apoptosis.
Two out of the four dual inhibition-sensitive cell lines
showed comparable cytotoxicity to that achieved with
continuous administration of dual inhibition when the
MEK inhibitor was administered for short periods
(15 min) in combination with continuous PI3K inhibitor
treatment. The increased cytotoxicity occurred even
though the effects of the MEK inhibitor were quickly
reversed (<6 h) after wash-out of the drug. Meanwhile
H3122, an ALK translocated cell line, showed apoptosis
in response to short concurrent administration of the
drugs even though longer concurrent administration led
to maximal cytotoxicity. Interestingly, short courses of
ALK inhibition (15 min) induced comparable cytotox-
icity to long administration of either an ALK inhibitor or
a dual inhibitor combination, even though the ALK
inhibitor is reversible in its mode of action and some
recovery of the target inhibition is known to occur
within 6h. In the light of our in vitro data, one could
hypothesize that even a short course of dual inhibitor
administration could have similar clinical effects with
better tolerability. Analogously, a recent work has shown
that intermittent administration of concurrent PI3K and
MEK inhibition can induce robust growth inhibition in
cancer cell lines [24]. Better alternative dosing schedules
for achieving clinical tolerability could also enable the
use of higher doses of the drugs, leading to stronger in-
hibition of the target. Short but more significant targetinhibition is likely to be more efficient than sub-
maximal inhibition for longer periods. Our data point to
the importance of maximal inhibition of the target and a
preferential role for longer PI3K-AKT pathway inhib-
ition when dual inhibition is used. These data are based
only on in vitro models, however, and correlation with
the in vivo situation is not always a straightforward
matter.
The interconnectivity of the PI3K-AKT-mTOR and
RAS-RAF-MEK-ERK pathways makes the idea of their
concurrent dual inhibition an appealing one. The
present cell signaling experiments also showed high
interconnectivity of these two pathways, since in many
instances inhibition of one pathway resulted in concur-
rent feedback activation of the other. Furthermore, an-
other MEK inhibition-induced feedback mechanism was
identified in the MDA-MB231 cell line which led to the
activation of 4E-BP1 independently of PI3K-AKT. Previ-
ous studies have suggested that the PI3K-AKT-mTOR
and RAS-RAF-MEK-ERK pathway signals converge at
4E-BP1, and that its inhibition may be a major determin-
ant of the efficiency of dual inhibition [25]. Conversely,
we did not find any correlation between the efficiency of
dual inhibition and 4E-BP1 downregulation, since the
4E-BP1 signal correlated significantly only with PI3K-
AKT-mTOR activity and cytotoxicity occurred without
it being downregulated. In also, some of the treatment
schedules induced marked cytotoxicity in the H3122 and
MDA-MB231 cell lines without the induction of any
marked 4E-BP1downregulation.
Conclusions
The most important findings to emerge from this inves-
tigation of the concurrent dual inhibition of PI3K and
MEK for cancer therapy purposes are the fact that alter-
native dosing schedules result in comparable cytotoxicity
to that achieved with continuous treatment schedules,
and that the responses to dual inhibition can be achieved
in multiple cancer genotypes. The present preclinical
data may offer new leads for clinical progress towards
more efficient and tolerable cancer therapies.
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